Laurence Turka

2021

In 2021, Laurence Turka earned a total compensation of $2M as Chief Scientific Officer and Head of Research and Translational Medicine at Rubius Therapeutics, a 16% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$189,136
Option Awards$1,048,858
Salary$425,850
Stock Awards$356,108
Other$11,564
Total$2,031,516

Turka received $1M in option awards, accounting for 52% of the total pay in 2021.

Turka also received $189.1K in non-equity incentive plan, $425.9K in salary, $356.1K in stock awards and $11.6K in other compensation.

Rankings

In 2021, Laurence Turka's compensation ranked 5,996th out of 12,415 executives tracked by ExecPay. In other words, Turka earned more than 51.7% of executives.

ClassificationRankingPercentile
All
5,996
out of 12,415
52nd
Division
Manufacturing
2,540
out of 5,505
54th
Major group
Chemicals And Allied Products
1,110
out of 2,375
53rd
Industry group
Drugs
988
out of 2,096
53rd
Industry
Biological Products, Except Diagnostic Substances
240
out of 449
47th
Source: SEC filing on March 30, 2022.

Turka's colleagues

We found four more compensation records of executives who worked with Laurence Turka at Rubius Therapeutics in 2021.

2021

Pablo Cagnoni

Rubius Therapeutics

Chief Executive Officer

2021

Dannielle Appelhans

Rubius Therapeutics

Chief Operating Officer

2021

Maiken Keson-Brookes

Rubius Therapeutics

Chief Legal Officer

2021

Jose Carmona

Rubius Therapeutics

Chief Financial Officer

News

In-depth

You may also like